NASDAQ: AKBA | Healthcare / Biotechnology / USA |
0.3986 | -0.0171 | -4.11% | Vol 3.16M | 1Y Perf -83.82% |
Aug 11th, 2022 16:00 DELAYED |
BID | 0.3951 | ASK | 0.4050 | ||
Open | 0.4150 | Previous Close | 0.4157 | ||
Pre-Market | - | After-Market | 0.40 | ||
- - | 0.00 -0.88% |
Target Price | 1.75 | Analyst Rating | Hold 3.00 | |
Potential % | 339.04 | Finscreener Ranking | ☆ 30.35 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ☆ 32.06 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ☆ 26.14 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 3.23 | Earnings Rating | Strong Sell | |
Market Cap | 73.28M | Earnings Date | 4th Aug 2022 | |
Alpha | -0.04 | Standard Deviation | 0.24 | |
Beta | 1.47 |
Today's Price Range 0.39510.4199 | 52W Range 0.30003.35 | 5 Year PE Ratio Range -3.00-1.90 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 0.91% | ||
1 Month | -11.38% | ||
3 Months | -3.44% | ||
6 Months | -77.48% | ||
1 Year | -83.82% | ||
3 Years | -90.92% | ||
5 Years | -97.21% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -64.21 | |||
ROE last 12 Months | -241.73 | |||
ROA (5Y Avg) | -32.51 | |||
ROA last 12 Months | -48.84 | |||
ROC (5Y Avg) | -57.75 | |||
ROC last 12 Months | -110.18 | |||
Return on invested Capital Q | -30.69 | |||
Return on invested Capital Y | -29.89 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 3.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.30 | ||||
2.96 | ||||
0.43 | ||||
10.50 | ||||
-0.50 | ||||
-1.18 | ||||
-0.60 | ||||
0.14 | ||||
38.06M | ||||
Forward PE | -1.16 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.90 | ||||
1.20 | ||||
0.56 | ||||
5.18 | ||||
-26.20 | ||||
Leverage Ratio | 10.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
32.70 | ||||
-115.70 | ||||
-98.70 | ||||
-92.00 | ||||
-83.74 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
170.06M | ||||
0.93 | ||||
-5.99 | ||||
34.66 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.31 | 0.23 | 174.19 |
Q01 2022 | -0.27 | -0.35 | -29.63 |
Q04 2021 | -0.33 | -0.40 | -21.21 |
Q03 2021 | -0.32 | -0.34 | -6.25 |
Q02 2021 | -0.30 | -0.51 | -70.00 |
Q01 2021 | -0.33 | -0.45 | -36.36 |
Q04 2020 | -0.43 | -0.60 | -39.53 |
Q03 2020 | -0.23 | -0.42 | -82.61 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.29 | -70.59 | Negative |
9/2022 QR | -0.17 | -6.25 | Negative |
12/2022 FY | -0.88 | -33.33 | Negative |
12/2023 FY | -0.34 | 8.11 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.29 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 3.16M |
Shares Outstanding | 183.85K |
Shares Float | 181.56M |
Trades Count | 5.86K |
Dollar Volume | 1.28M |
Avg. Volume | 6.72M |
Avg. Weekly Volume | 5.96M |
Avg. Monthly Volume | 4.37M |
Avg. Quarterly Volume | 9.84M |
Akebia Therapeutics Inc. (NASDAQ: AKBA) stock closed at 0.3986 per share at the end of the most recent trading day (a -4.11% change compared to the prior day closing price) with a volume of 3.16M shares and market capitalization of 73.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 360 people. Akebia Therapeutics Inc. CEO is John P. Butler.
The one-year performance of Akebia Therapeutics Inc. stock is -83.82%, while year-to-date (YTD) performance is -82.36%. AKBA stock has a five-year performance of -97.21%. Its 52-week range is between 0.3 and 3.35, which gives AKBA stock a 52-week price range ratio of 3.23%
Akebia Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 2.96, a price-to-sale (PS) ratio of 0.43, a price to cashflow ratio of 10.50, a PEG ratio of 2.32, a ROA of -48.84%, a ROC of -110.18% and a ROE of -241.73%. The company’s profit margin is -83.74%, its EBITDA margin is -98.70%, and its revenue ttm is $170.06 Million , which makes it $0.93 revenue per share.
Of the last four earnings reports from Akebia Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Akebia Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Akebia Therapeutics Inc. is Hold (3), with a target price of $1.75, which is +339.04% compared to the current price. The earnings rating for Akebia Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akebia Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akebia Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.00, ATR14 : 0.04, CCI20 : -15.37, Chaikin Money Flow : -0.07, MACD : 0.00, Money Flow Index : 41.57, ROC : -1.58, RSI : 39.32, STOCH (14,3) : 52.18, STOCH RSI : 0.60, UO : 54.30, Williams %R : -47.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akebia Therapeutics Inc. in the last 12-months were: David A. Spellman (Sold 8 203 shares of value $17 689 ), Dell Faulkingham (Sold 13 184 shares of value $28 515 ), John P. Butler (Sold 79 026 shares of value $171 143 ), Michel Dahan (Sold 14 660 shares of value $31 718 ), Nicole R. Hadas (Sold 21 062 shares of value $45 615 ), Steven C. Gilman (Sold 4 567 shares of value $1 653 ), Steven Keith Burke (Sold 16 098 shares of value $35 513 ), Violetta Cotreau (Sold 9 779 shares of value $21 838 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Hold | Hold |
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.
CEO: John P. Butler
Telephone: +1 617 871-2098
Address: 245 First Street, Cambridge 02142, MA, US
Number of employees: 360
Mon, 16 May 2022 11:26 GMT Akebia Therapeutics (AKBA) Receives a Hold from Mizuho Securities
- TipRanks. All rights reserved.Mon, 16 May 2022 10:28 GMT Akebia Therapeutics (AKBA) Gets a Hold Rating from H.C. Wainwright
- TipRanks. All rights reserved.Tue, 10 May 2022 16:05 GMT Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Cerevel Therapeutics Holdings (CERE)
- TipRanks. All rights reserved.Tue, 10 May 2022 02:15 GMT Akebia Therapeutics (AKBA) Gets a Hold Rating from Mizuho Securities
- TipRanks. All rights reserved.Mon, 11 Apr 2022 12:13 GMT Why Was Akebia Trading Lower in Pre-Market Session
- TipRanks. All rights reserved.Thu, 07 Apr 2022 15:05 GMT Akebia Therapeutics (AKBA) Gets a Hold Rating from Needham
- TipRanks. All rights reserved.Thu, 31 Mar 2022 11:35 GMT Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and TFF Pharmaceuticals (TFFP)
- TipRanks. All rights reserved.Thu, 31 Mar 2022 00:25 GMT Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Brainstorm Cell Therapeutics (BCLI)
- TipRanks. All rights reserved.Mon, 21 Mar 2022 09:05 GMT Analysts Offer Insights on Healthcare Companies: and Akebia Therapeutics (AKBA)
- TipRanks. All rights reserved.Wed, 02 Mar 2022 04:45 GMT Akebia Therapeutics (AKBA) Received its Third Buy in a Row
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.